

Interview Summary

Application No.

10/024,541

Applicant(s)

QI, ZHIHONG HELENA

Examiner

Devesh Khare

Art Unit

1623

All participants (applicant, applicant's representative, PTO personnel):

(1) Devesh Khare. (3) _____.

(2) Donald Lucas. (4) _____.

Date of Interview: 16 December 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.

If Yes, brief description: _____.

Claim(s) discussed: _____.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments:

(1) Claims 9-12 have been cancelled without prejudice.

(2) In each of claims 1 and 5, in lines 1-2, phrase "a" has been placed before phrase "guest" and phrase "molecule" has been placed after phrase "guest".

(2) In each of claims 1 and 5, in line 3, phrase "said" has been placed before phrase "guest" and in line 7, phrase "molecule" has been placed after phrase "guest".

(3) In each of claims 3 and 7, phrase "wherein the cyclodextrin is a modified cyclodextrin, an unmodified cyclodextrin, a branched cyclodextrin, an unbranched cyclodextrin, or a combination thereof" has been replaced by the phrase "wherein the cyclodextrin is a α -cyclodextrin, a β -cyclodextrin, or a γ -cyclodextrin." (4) In claim 1, line 5, phrase "C" has been placed after phrase "100"..